Emerging drugs for autonomic dysfunction in Parkinson's disease
- Autores
- Pérez Lloret, Santiago; Rey, Verónica; Pavy-Le Traon, Anne; Rascol, Olivier
- Año de publicación
- 2013
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión enviada
- Descripción
- Fil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina
Fil: Rey, Verónica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Rey, Verónica. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina
Fil: Pavy-Le Traon, Anne. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Fil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia
Abstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments - Fuente
- Preprint del documento publicado en Expert Opinion on Emerging Drugs, Vol. 18, Nro. 1, 2013
- Materia
-
TOXINA BOTULIMICA
ESTREÑIMIENTO
DOMPERIDONA
DROXIDOPA
DISFUNCION ERECTIL
FLUDROCORTISONA
INCONTINENCIA
HIPOTENSION ORTOSTATICA
ENFERMEDAD DE PARKINSON
DISFUNCION URINARIA - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Pontificia Universidad Católica Argentina
- OAI Identificador
- oai:ucacris:123456789/1667
Ver los metadatos del registro completo
id |
RIUCA_90e72abf960eec6b7294c344613795af |
---|---|
oai_identifier_str |
oai:ucacris:123456789/1667 |
network_acronym_str |
RIUCA |
repository_id_str |
2585 |
network_name_str |
Repositorio Institucional (UCA) |
spelling |
Emerging drugs for autonomic dysfunction in Parkinson's diseasePérez Lloret, SantiagoRey, VerónicaPavy-Le Traon, AnneRascol, OlivierTOXINA BOTULIMICAESTREÑIMIENTODOMPERIDONADROXIDOPADISFUNCION ERECTILFLUDROCORTISONAINCONTINENCIAHIPOTENSION ORTOSTATICAENFERMEDAD DE PARKINSONDISFUNCION URINARIAFil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaFil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; ArgentinaFil: Rey, Verónica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaFil: Rey, Verónica. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; ArgentinaFil: Pavy-Le Traon, Anne. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaFil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; FranciaAbstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatmentsTaylor and Francis2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/166710.1517/14728214.2013.766168Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667Preprint del documento publicado en Expert Opinion on Emerging Drugs, Vol. 18, Nro. 1, 2013reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:21Zoai:ucacris:123456789/1667instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:21.964Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse |
dc.title.none.fl_str_mv |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
title |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
spellingShingle |
Emerging drugs for autonomic dysfunction in Parkinson's disease Pérez Lloret, Santiago TOXINA BOTULIMICA ESTREÑIMIENTO DOMPERIDONA DROXIDOPA DISFUNCION ERECTIL FLUDROCORTISONA INCONTINENCIA HIPOTENSION ORTOSTATICA ENFERMEDAD DE PARKINSON DISFUNCION URINARIA |
title_short |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
title_full |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
title_fullStr |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
title_full_unstemmed |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
title_sort |
Emerging drugs for autonomic dysfunction in Parkinson's disease |
dc.creator.none.fl_str_mv |
Pérez Lloret, Santiago Rey, Verónica Pavy-Le Traon, Anne Rascol, Olivier |
author |
Pérez Lloret, Santiago |
author_facet |
Pérez Lloret, Santiago Rey, Verónica Pavy-Le Traon, Anne Rascol, Olivier |
author_role |
author |
author2 |
Rey, Verónica Pavy-Le Traon, Anne Rascol, Olivier |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
TOXINA BOTULIMICA ESTREÑIMIENTO DOMPERIDONA DROXIDOPA DISFUNCION ERECTIL FLUDROCORTISONA INCONTINENCIA HIPOTENSION ORTOSTATICA ENFERMEDAD DE PARKINSON DISFUNCION URINARIA |
topic |
TOXINA BOTULIMICA ESTREÑIMIENTO DOMPERIDONA DROXIDOPA DISFUNCION ERECTIL FLUDROCORTISONA INCONTINENCIA HIPOTENSION ORTOSTATICA ENFERMEDAD DE PARKINSON DISFUNCION URINARIA |
dc.description.none.fl_txt_mv |
Fil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina Fil: Rey, Verónica. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia Fil: Rey, Verónica. Pontificia Universidad Católica Argentina. Laboratorio de Clínica Farmacológica y Epidemiología; Argentina Fil: Pavy-Le Traon, Anne. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia Fil: Rascol, Olivier. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia Abstract: Autonomic dysfunction, including orthostatic hypotension (OH), sialorrhea, sexual dysfunction, urinary dysfunction and constipation is a common feature of Parkinson’s disease (PD). Even though its treatment has been recognized as a major unmet need in PD, there is a paucity of clinical trials to assess their treatment. Areas covered: Evidence about the efficacy and safety of available treatments for autonomic dysfunction is summarized. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of each disorder in PD. Proof-of-concept trials and circumstantial evidence about treatments for autonomic dysfunction as well as upcoming clinical trials are discussed. Finally, critical aspects of clinical trials design are considered. Expert opinion: Botulinum toxin (BTX) or glycopyrrolate might be used for sialorrhea whereas macrogol could be useful in constipation. There is preliminary evidence suggesting that fludrocortisone, domperidone, droxidopa or fipamezole may be effective for the treatment of OH. Tropicamide, clonidine or radiotherapy are under development for sialorrhea. Sildenafil may be effective for the treatment of erectile dysfunction; BTX or behavioral therapy for urinary incontinence and lubiprostone and probiotics for constipation. Sound clinical trials are needed in order to allow firm evidence-based recommendations about these treatments |
description |
Fil: Pérez Lloret, Santiago. Universidad de Toulouse III. Hospital Universitario. Departamento de Farmacología Clínica y Neurociencia; Francia |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/submittedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
submittedVersion |
dc.identifier.none.fl_str_mv |
https://repositorio.uca.edu.ar/handle/123456789/1667 10.1517/14728214.2013.766168 Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667 |
url |
https://repositorio.uca.edu.ar/handle/123456789/1667 |
identifier_str_mv |
10.1517/14728214.2013.766168 Pérez Lloret, S., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease [en línea]. Preprint del documento publicado en Expert Opinion on Emerging Drugs. 2013, 18 (1). doi:10.1517/14728214.2013.766168. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1667 |
dc.language.none.fl_str_mv |
eng eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Taylor and Francis |
publisher.none.fl_str_mv |
Taylor and Francis |
dc.source.none.fl_str_mv |
Preprint del documento publicado en Expert Opinion on Emerging Drugs, Vol. 18, Nro. 1, 2013 reponame:Repositorio Institucional (UCA) instname:Pontificia Universidad Católica Argentina |
reponame_str |
Repositorio Institucional (UCA) |
collection |
Repositorio Institucional (UCA) |
instname_str |
Pontificia Universidad Católica Argentina |
repository.name.fl_str_mv |
Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina |
repository.mail.fl_str_mv |
claudia_fernandez@uca.edu.ar |
_version_ |
1836638330863747072 |
score |
13.13397 |